Hence, the mitochondrial mechanisms through which MTFP1 ablation protects against hepatic steatosis appears to be functionally distinct from pathways currently being pursued as therapeutic interventions for MASLD and associated pathologies5,77,78. The gene discussed is MTFP1; the disease is metabolic dysfunction-associated steatotic liver disease.